Summary
Flavone 8-acetic acid (FAA) represents a novel chemical structure undergoing clinical trials as an anticancer drug. Its unusual properties tend to distinguish it from a conventional cytotoxic compound, particularly in the response of solid murine tumours; as a consequence, novel mechanisms of action are currently under investigation. In this review we summarised these mechanisms into one of the three categories (a) direct cytotoxicity, (b) biologic response modifier and (c) pharmacologic effector and considered the evidence for and against each. FAA is cytotoxic to tumour cells in vitro, but only at high concentrations and after long exposures. In vivo it is considerably more cytotoxic to the same cells, and it is unlikely that direct cytotoxicity alone can account for this difference. FAA stimulates NK cell activity, induces interferon α and synergises with interleukin 2 in the treatment of murine renal cancer. However, a definite link between immunomodulation and antitumour activity has still to be confirmed. Perhaps FAA's most unusual property is its ability to reduce tumour blood flow dramatically, which may provide the appropriate conditions for reactive chemistry to occur. Finally, a combination of the above mechanisms probably work together in producing the drug's unique spectrum of antitumour activity.
Similar content being viewed by others
References
Bibby MC, Double JA, Phillips RM, Loadman PM (1987) Factors involved in the anticancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer 55: 159
Bibby MC, Double JA, Phillips RM, Loadman PM, Gummer JA (1988) Prog Clin Biol Res 280: 243
Bissery M-C, Valeriote FA, Chabot GC, Crissman JD, Yost C, Corbett TH (1988) Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo. Cancer Res 44:1279
Capolongo LS, Balconi G, Ubezio P, Giavazzi R, Taraboletti G, Regoresi A, Yoder OC, D'Incalci M (1987) Antiproliferative properties of flavone actic acid (NSC 347512) (LM975), a new anticancer agent. Eur J Cancer Clin Oncol 23:1529
Chabot G, Rutkowski K (1988) Activation of flavone 8-acetic acid to cytotoxic metabolites in vitro. Proc Am Assoc Cancer Res 29:484
Ching L-M, Baguley BC (1987) Induction of natural killer cell activity by the antitumour compound flavone acetic acid. Eur J Cancer Clin Oncol 23:1047
Corbett TH, Bissery M-C, Wozniak A, Plowman J, Polin L, Tapazoglau E, Dieckman J, Valeriote FA (1986) Activity of flavone acetic acid (NSC 347512) against solid tumours of mice. Invest New Drugs 4:207
Cummings J, Smyth JF, Double JA, Farmer P, Kaye SB (1988) Identification and characterisation of the major human metabolites of flavone acetic acid (FAA). Proc Am Assoc Cancer Res 29:486
Damia G, Zanette ML, Rossi C, Mandelli R, Ferrari A, D'Incalci M (1988) Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemother Pharmacol 22:47
Double JA, Bibby MC, Phillips RM (1987) Site dependent sensitivity to flavone acetic acid (LM 975). Br J Cancer 56: 215
Duke CV, Double JA, Bibby MC (1989) Flavone acetic acid (FAA) (LM975, NSC 347512) induces rapid massive necrosis in a murine transplantable adenocarcinoma. Proc Br Oncol Assoc (in press)
EORTC Early Clinical Trials Group (1988)
Evelhoch JL, Bissery M-C, Chabot GC, Simpson NE, McCoy CL, Corbett TH (1988) Flavone acetic acid (NSC-347512)-induced modulation of tumour physiology monitored by in vivo NMR spectroscopy. Proc Am Assoc Cancer Res 29:502
Finlay GJ, Smith GP, Fray LM, Baguley BC (1988) Effect of flavone acetic acid on Lewis Lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst 80:241
Halvin K, Craig J, Kuhn J, Bodt D, Weiss G, Koeller G, Clark G, Van Hoff D (1988) Phase I clinical and pharmacokinetic trial of flavone acetic acid (FAA). Proc Am Assoc Cancer Res 29:221
Havsteen B (1983) Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 32:1141
Kerr DJ, Kaye SB, Graham J, Cassidy J, Harding M, Setanoinas A, McGrath JC, Vezin WR, Cunningham D, Forrest G, Soukop M (1986) Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res 46:3142
Kerr DJ, Kaye SB, Cassidy J, Bradley C, Rankin EM, Adams L, Setanoians A, Young T, Forrest G, Soukop M, Clavel M (1987) Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47:6776
Melink T, Egorin M, Conley B, Sinibaldi V, Zuhowski E, Cohen A, Van Echo DA (1987) Phase I trial and pharmacokinetics of flavone acetic acid (NSC 347512) (FAA) administered by 1-hour infusion. Proc Am Soc Clin Oncol 6:39
O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, Leyland-Jones B (1987) Flavone acetic acid (LM975, NSC 347512), a novel antitumour agent. Cancer Chemother Pharmacol 19:6
Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD (1986) Flavone acetic acid: a novel agent with preclinical antitumour activity, against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70:631
Rabinovitz M (1988) The structure of flavone-8-acetic acid, a chemotherapeutic agent and its application to drug design. J Enzyme Inhibit 2:151
Rinehart J, Staubus AE, Malspeis L, Greven M (1988) In vitro and in vivo immunologic effects of flavone acetic acid in man. Proc Am Assoc Cancer Res 29:399
Smith GP, Calveley SB, Smith MJ, Baguley BC (1987) Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23:1209
Trader MW, Harrison SD Jr, Laster WR Jr, Grisudd DP Jr (1987) Cross resistance and collateral sensitivity of drug resistant P388 and L1210 leukemias to flavone acetic acid (FAA, NSC 347512) in vivo. Proc Am Assoc Cancer Res 28:312
Urba WJ, Longo DL, Lombarbo Fa, Weiss RB (1988) Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J Natl Cancer Inst 86:521
Vatsis KP, Deutsch J, Gelboin HV, Coon MJ (1980) In: Drug oxidations and chemical carcinogenesis, vol 2. Academic Press, New York, p 1065
Wiltrout RH, Horning RL (1988) Natural products as antitumour agents: direct versus indirect mechanisms of activity of flavonoids. J Natl Cancer Inst 80:220
Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Horning RL (1988) Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for the treatment of murine renal cancer. J Immunol 140:3261
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cummings, J., Smyth, J.F. Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother. Pharmacol. 24, 269–272 (1989). https://doi.org/10.1007/BF00304756
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00304756